Myeloma Canada has given me a much clearer perspective on the patient journey living with a disease, and how patients display such hope and resilience. Traditionally from the clinical research side, we don’t have much contact with patient groups. Having that opportunity - and closely interacting with Myeloma Canada - helps broaden your view. I have had the opportunity to present our pipeline to Myeloma Canada’s patient groups and interact with the patients. For me, that interaction is very important. As I said, we don’t often have that chance and it is so very valuable.